{
    "clinical_study": {
        "@rank": "110861", 
        "arm_group": [
            {
                "arm_group_label": "TDT067", 
                "arm_group_type": "Experimental", 
                "description": "Active treatment"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to establish a clinical bridge to Lamisil\u00ae tablets by conducting a\n      clinical pharmacokinetic (PK) study comparing the systemic exposure of a Lamisil\u00ae tablet\n      with that of with TDT 067 under maximal use conditions.\n\n      Under maximal use conditions in onychomycotic subjects, the aim is to confirm that there are\n      significantly lower plasma levels of terbinafine and its major metabolites after a topical\n      administration of TDT 067 for 28 days in comparison with a single oral 250 mg Lamisil\u00ae\n      tablet."
        }, 
        "brief_title": "TDT 067 Open Label Multi-Dose Onychomycosis Study", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Onychomycosis", 
        "condition_browse": {
            "mesh_term": "Onychomycosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must be between 18 and 65 years of age inclusive, of any race, and of either\n             sex.\n\n          -  Male subjects only: Male subjects must use a reliable form of contraception during\n             their participation in the trial and for 3 months after their last dose of study\n             drug.\n\n          -  Female subjects only: Either of non-childbearing potential (i.e. either surgically\n             sterilized or post menopausal) or must be using adequate contraception, have a\n             negative pregnancy test prior to start of dosing, and must agree to continue to use\n             this method of contraception until 3 months after the last dose. Acceptable\n             contraceptive methods are oral contraceptive, IUD, or diaphragm with spermicide\n             (unless anatomically sterile).\n\n          -  Subjects must be in good general health as confirmed by a medical history and\n             physical examination.\n\n          -  Subjects must have 2 big toes with nails that have the potential to be clipped to\n             provide nail samples.\n\n          -  Subjects must have clinically diagnosed distal subungual onychomycosis of the\n             toenails; at least 5 nails in total must present with onychomycotic signs\n             (onycholysis, subungual hyperkeratosis) including extensive involvement (\u226550%) of\n             both large nails and mycological confirmation (positive KOH microscopy) from 1 of the\n             large nails.\n\n          -  Subject must sign a statement of informed consent.\n\n          -  Subjects must be able to understand the requirements of the study, abide by the\n             restriction, and return for all of the required examinations\n\n        Exclusion Criteria:\n\n          -  Subjects lacking any toes.\n\n          -  Subjects with known hypersensitivity to terbinafine or any of the excipients in the\n             TDT 067.\n\n          -  Subjects with symptomatic tinea pedis requiring treatment.\n\n          -  Subjects with any medical, neurological, or psychiatric conditions that in the\n             opinion of the Investigator would make the subject unsuitable for enrollment onto the\n             study.\n\n          -  Subjects with chronic or active liver disease, as well as subjects with elevated\n             liver function tests above normal for the testing laboratory.\n\n          -  Subjects with renal impairment (creatinine clearance \u226450 mL/min).\n\n          -  Subjects who have received terbinafine tablets within 12 months or topical\n             terbinafine (cream, solution/spray, or gel) within 6 months prior to screening visit;\n             subjects who have received other oral antifungals within 4 months or other topical\n             antifungals within 1 month.\n\n          -  Subjects who have participated within the previous 3 months in a clinical trial for\n             the systemic or topical treatment of onychomycosis.\n\n          -  Subjects being treated with rifampin or cimetidine.\n\n          -  Subjects being treated with an investigational drug within 1 month prior to study\n             start.\n\n          -  Subjects with psoriasis or history of psoriasis.\n\n          -  Subjects with nail dystrophy or other nail abnormalities other than onychomycosis.\n\n          -  Subjects with serious concurrent disease that might prevent completion of the trial.\n\n          -  Subjects who are pregnant (confirmed by pregnancy test) or who plan to become\n             pregnant within the study timeframe or who are nursing.\n\n          -  Subjects who cannot read, understand, or sign the informed consent form or the\n             instructions for applying and removing the study formulations.\n\n          -  Subjects who cannot apply the product to their toenails.\n\n          -  Subjects who do not wish to provide nail clippings.\n\n          -  Subjects who cannot or will not provide adequate blood and urine samples.\n\n          -  Subjects using any nail polish products or other nail cosmetic products on any of the\n             toenails designated for treatment within 7 days prior to the start of treatment and\n             who are unwilling to discontinue use of these products for the duration of this\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790165", 
            "org_study_id": "CL-067-II-02"
        }, 
        "intervention": {
            "arm_group_label": "TDT067", 
            "description": "Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet", 
            "intervention_name": "TDT067 and Lamisil", 
            "intervention_type": "Drug", 
            "other_name": "Lamisil"
        }, 
        "intervention_browse": {
            "mesh_term": "Terbinafine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Onychomycosis", 
            "Open Label", 
            "PK"
        ], 
        "lastchanged_date": "February 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase II Open Label Multiple-Dose Study of the Safety and Pharmacokinetics of TDT 067 Under Conditions of Maximal Use in Subjects With Distal Subungual Onychomycosis of the Toenails", 
        "overall_official": {
            "affiliation": "Academic Dermatology Assoc", 
            "last_name": "Eduardo Tschen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cmax, Tmax, AUC0-12, AUC0-24, Cmax Ratio (day 28/day 35) were evaluated", 
            "measure": "PK", 
            "safety_issue": "No", 
            "time_frame": "35 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Celtic Pharma Development Services", 
        "sponsors": {
            "collaborator": {
                "agency": "PPD", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Celtic Pharma Development Services", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}